Arvinas, Inc.

Hopes that Arvinas/Pfizer’s estrogen receptor-targeting protein degrader vepdegestrant will show improved efficacy in breast cancer over selective estrogen receptor degraders (SERDs) appear dimmer fol

AstraZeneca has declared success for the first Phase III study of its breast cancer drug, camizestrant, giving it an edge over rival oral SERD candidates. The topline results from the SERENA-6 trial r

Pfizer/Arvinas’s VERITAC-2 Study Of Vepdegestrant In 2025, the first Phase III clinical readout for a PROTAC degrader is expected in an important milestone for the targeted protein degradation (TPD)

With the business year almost complete, a review of biopharmaceutical dealmaking showed that Novartis, in particular, enjoyed a very productive year with 21 transactions overall, including six acquisi